The Short Answer
Tesamorelin and ipamorelin both raise circulating growth hormone, but they do it through two different receptors, and that single fact drives every other difference between them. Tesamorelin is an analogue of growth hormone-releasing hormone acting at the GHRH receptor. Ipamorelin is a selective secretagogue acting at the ghrelin receptor, GHS-R1a.
They are not substitutes for one another. They have different origins, different research literatures, different endocrine signatures, and different regulatory positions. Figures reported for one carry no implication for the other.
Research use only. Both compounds are supplied by AminoCore Research for laboratory research. Neither is intended for human or veterinary use. This comparison summarises published research; it is not guidance for administration.
Side-by-Side
| Tesamorelin | Ipamorelin | |
|---|---|---|
| Class | GHRH analogue | Growth hormone secretagogue (GHRP) |
| Receptor | GHRH receptor | Ghrelin receptor (GHS-R1a) |
| Structure | hGHRH 1-44 with trans-3-hexenoic acid on N-terminal tyrosine | Pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2 |
| Molecular weight | ≈5,135.9 g/mol | ≈711.9 g/mol |
| Half-life | Tens of minutes | Approximately 2 hours |
| Regulatory status (US) | Approved as Egrifta for one narrow indication | No marketing authorisation; investigational only |
| Clinical trial base | Multiple randomised controlled trials in humans | Preclinical and early-phase; no pivotal human programme |
| Selectivity note | Acts on the physiological GHRH pathway | Characterised as sparing cortisol and prolactin release |
Mechanism: Two Doors Into the Same Room
Growth hormone release from the anterior pituitary is governed by two opposing inputs — growth hormone-releasing hormone, which stimulates it, and somatostatin, which restrains it. Ghrelin acts as a third input, amplifying release through its own receptor.
Tesamorelin enters through the first door. It is a stabilised copy of the body's own releasing hormone, modified so that enzymatic degradation is slowed enough to be useful. Because it engages the physiological pathway, the resulting release retains the pulsatile character of native secretion and remains subject to somatostatin's restraint.
Ipamorelin enters through the ghrelin door. It was described as the first selective growth hormone secretagogue, and its defining characteristic in that original work was what it did not do: at amounts producing growth hormone release, it did not produce the adrenocorticotropic hormone and cortisol elevation seen with earlier peptides in its class (Raun et al., Eur J Endocrinol 1998, PMID 9849822). That selectivity is the reason ipamorelin remained of interest while several predecessors did not.
Because the two act at different receptors, their effects are additive rather than redundant — a point noted throughout the secretagogue literature and the reason the two classes are frequently studied together (Baldelli et al., Endocrine 2001, PMID 11322508).
Evidence Base: The Asymmetry That Matters Most
This is where the comparison stops being symmetrical, and it is the single most important thing to understand about these two compounds.
Tesamorelin has a pivotal human programme. A 412-participant randomised, double-blind, placebo-controlled trial published in the New England Journal of Medicine established its effect on visceral adipose tissue in adults with HIV-associated abdominal fat accumulation (Falutz et al., 2007, PMID 18057338), followed by a 52-week extension (PMID 18690162) and later work extending into hepatic endpoints (Stanley et al., Lancet HIV 2019, PMID 31611038). That body of work is why the compound has an approved indication.
Ipamorelin does not. Its literature is predominantly preclinical — rodent models of bone formation under glucocorticoid exposure (Andersen et al., Growth Horm IGF Res 2001, PMID 11735244), nitrogen balance and urea synthesis in steroid-exposed rats (Aagaard et al., 2009, PMID 19231263), and medicinal chemistry work deriving further analogues from its scaffold (Ankersen et al., J Med Chem 1998, PMID 9733495). No pivotal human programme was completed, and no regulatory authorisation exists anywhere.
The practical consequence: a claim about tesamorelin can often be traced to a controlled human trial. An equivalent claim about ipamorelin usually cannot. When the two are presented side by side as interchangeable options, that asymmetry is what gets lost.
Amounts Reported in the Literature
For tesamorelin, published trials consistently report 2 mg subcutaneously once per day, studied exclusively in adults with HIV-associated abdominal fat accumulation. We cover the full citation set, half-life data and documented adverse events in tesamorelin dosage: what the research literature reports.
For ipamorelin, no comparable figure exists. There is no established amount in humans for any indication, because there is no completed pivotal programme from which one could be derived. Amounts circulating in non-clinical discussion are not traceable to controlled trials, and this page will not repeat them.
That absence is not an oversight in the literature. It is the literature.
Endocrine Signature
Because tesamorelin engages the GHRH pathway, its downstream signature is a growth hormone pulse followed by an IGF-1 rise, with somatostatin feedback intact. Trials tracked IGF-1 as a pharmacodynamic marker, and glucose regulation was monitored throughout because growth hormone opposes insulin action.
Ipamorelin's signature, as originally characterised, is a growth hormone pulse with comparatively little disturbance of cortisol and prolactin — the property that distinguished it from GHRP-6 and GHRP-2 in the same series. In the presets on our reconstitution calculator, this difference is why the two compounds carry different handling and frequency defaults.
Handling in the Laboratory
Both arrive as lyophilised powder and follow the same bench discipline: store the sealed vial at −20 °C protected from light, introduce bacteriostatic water down the vial wall rather than onto the powder cake, do not shake, and refrigerate reconstituted solution at 2–8 °C.
The meaningful handling difference is concentration arithmetic, which follows from the ninefold molecular weight gap and the different vial sizes the two are typically supplied in. Our tesamorelin calculator and the generic peptide calculator handle the conversion to insulin-syringe units for either compound.
Background on why these steps matter is covered in lyophilised peptides: what researchers need to know and temperature effects on peptides.
Choosing Between Them for Research Design
The right question is not which compound is stronger, but which receptor pathway the experiment is meant to interrogate.
If the research question concerns the GHRH axis, physiological pulsatility, or comparison against a human evidence base, tesamorelin is the compound with the literature behind it. If the question concerns the ghrelin receptor, secretagogue selectivity, or the cortisol-sparing property specifically, ipamorelin is the compound that property was defined on.
If the design calls for probing both pathways, that is a study of two mechanisms, and it should be reported as such rather than as a single combined intervention.
Further Reading
Full monographs: tesamorelin and ipamorelin. Related comparisons in this series include CJC-1295 DAC vs no-DAC and AOD-9604 vs HGH Fragment 176-191. For the meaning of the research-use designation, see what "for research use only" means.
